title: Migraine prevention.
abstract: Preventive medications reduce migraine frequency and severity, and improve migraine-specific quality of life. Recent evidence also suggests that these same medications enhance the patient's response to acute migraine therapies, and may also reduce the likelihood of developing chronic daily headache. However, many patients who should receive or be offered preventive treatment are not. Most patients can be successfully managed when patient and physician expectations are realistic and aligned, the selection of preventive medications is individualised, and the initiation and titration strategy is appropriate and carefully followed. Rational combinations of preventive medications may also be useful. This review provides an evidence and experience-based approach to the preventive treatment of migraine.
authors.affiliation: Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA. Dodick.David@mayo.edu
authors.forename: D W
authors.initials: DW
authors.lastname: Dodick
authors.forename: S D
authors.initials: SD
authors.lastname: Silberstein
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D001676:Biofeedback, Psychology; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D020773:Headache Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D010936:Plant Extracts / Q000008:administration & dosage
chemical_list: D000319:Adrenergic beta-Antagonists; D000927:Anticonvulsants; D010936:Plant Extracts